Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


The CF Foundation urges all states to include newborn screening for cystic fibrosis in test panels


Similar recommendations issued from the CDC based on benefits of early diagnosis

The Cystic Fibrosis Foundation today issued a recommendation for the implementation of routine cystic fibrosis (CF) screening in all newborns. In addition, the Centers for Disease Control and Prevention (CDC) issued a recommendation in its October 15 Morbidity and Mortality Weekly Report (MMWR) Reports and Recommendations that all states should consider routine screening for CF in all newborns. CF Foundation-supported research and peer-reviewed evidence conducted and gathered over the past two decades have demonstrated the benefits of newborn screening for CF. People with CF who are diagnosed at birth gain more weight and have better nutrition than those who are diagnosed later in life. Better nutrition and weight gain in children with CF has been linked to a slower decline in respiratory function, the primary cause of death in CF.

Advances in CF treatment and care, have had a significant impact on the length and quality of life for people with CF. Research on newborn screening for CF has shown further clinical benefit when therapeutic interventions were administered near the beginning of life. Early diagnosis allows a special high-calorie, high-fat diet, along with pancreatic enzyme and fat soluble vitamin supplementation to begin immediately, if needed, before digestive complications occur. Better nutrition has been linked to improved height and weight measurements, better pulmonary status, and cognitive benefits.

"It is imperative that states add newborn screening for CF to their test panels to give people with this disease the best odds at living longer, healthier lives," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "The CF Foundation is prepared to be a resource of knowledge and expertise for states as they consider this important recommendation and begin implementing newborn screening for CF."

Although new therapies and specialized care have extended the lives of people with CF, the average age of diagnosis--approximately 3 years--has remained the same. Traditionally, children with CF are not diagnosed unless CF has been present in a family’s history or until symptoms appear. In many cases, delayed diagnosis has resulted in irreversible nutritional and pulmonary morbidities. By making a CF diagnosis sooner, therapeutic interventions can minimize and postpone the development of symptoms, which can slow the progression of the disease.

Implementation of CF Newborn Screening

Participants in a recent workshop hosted by the CF Foundation discussed how to implement routine newborn screening for CF, as well as how the CF Foundation and its nationwide network of accredited care centers can ensure the best care for newborns before classic CF symptoms develop. The CF Foundation will work closely with state governments to urge the inclusion of CF on newborn screening test panels and will provide guidance on optimum test procedures and the elements of a comprehensive program. The CF Foundation also will encourage states to refer parents of newly diagnosed infants to its accredited care centers. These centers provide state-of-the-art specialty care and the opportunity for infants to benefit from medical advances. In addition, these centers will continue to track demographic, diagnostic, and treatment data via the CF Foundation’s national Patient Registry to further improve their care. Newborn screening for CF also will enable new treatment options for infants to be evaluated and developed.

"After reviewing and carefully considering the scientific evidence, the benefits of newborn screening for CF are now clear. We now must turn our attention to ensuring that parents of newborns diagnosed with CF are given the educational resources they need to care for their children and that they receive appropriate treatment from CF experts," said Preston W. Campbell, III, M.D., executive vice president of medical affairs of the CF Foundation. "I am eager to witness the improvements that CF newborn screening will inevitably bring to people with CF and am proud of the CF Foundation’s leadership role in this initiative."

The newborn screening tests for CF are not diagnostic tools. If the initial screen is positive, then further tests are done to rule out or confirm a CF diagnosis. Only a fraction of newborns with a positive initial screen ultimately will be diagnosed with CF. Currently, seven states conduct CF newborn screening in all newborns; three states screen for CF in some hospitals or populations; while two more states are now implementing CF screening programs. From 1990 to 1999, 1.46 million babies were screened for CF and 372 were ultimately diagnosed with CF. CF is one of the most common disorders identified in the newborn screening programs that include it in their testing.

Allison Tobin | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Earlier flowering of modern winter wheat cultivars

20.03.2018 | Agricultural and Forestry Science

Smithsonian researchers name new ocean zone: The rariphotic

20.03.2018 | Life Sciences

Molecular doorstop could be key to new tuberculosis drugs

20.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>